Bristol Myers Squibb has introduced Breyanzi® as the first CAR T cell therapy designed specifically for adults facing relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
Breyanzi® is characterized by its CD19-directed CAR T cell therapy, featuring a 4-1BB costimulatory domain. This specific targeting enhances the expansion and persistence of the CAR T cells in the patient's body.
Breyanzi® is made from the patient's own T cells, which are collected and genetically reengineered to become CAR T cells. This personalised approach offers a tailored treatment option for each patient.
Breyanzi® is delivered via infusion as a one-time treatment. This contrasts with conventional therapies, which often require ongoing treatment regimens.
Clinical trials have demonstrated that Breyanzi® provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have received at least two prior lines of therapy, including specific inhibitors.
The introduction of Breyanzi® expands access to CAR T cell therapy across a broad array of B-cell malignancies. This addresses the critical unmet need for effective treatment options in these conditions.
Breyanzi® represents a shift in the treatment paradigm for CLL and SLL. Instead of continuous therapy with sequential regimens to overcome drug resistance, Breyanzi® offers a one-time personalised T-cell based approach that has the potential to provide complete and lasting remission.
